



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

The Honorable Bart Stupak
Chairman
Subcommittee on Oversight and Investigations
Committee on Energy and Commerce
House of Representatives
Washington, D.C. 20515-6115

AUG 23 2007

Dear Mr. Chairman:

Thank you for your letter of July 5, 2007, co-signed by Representative John D. Dingell, Chairman, Committee on Energy and Commerce, requesting specific information and documents related to Avandia (rosiglitazone maleate) and Actos (pioglitazone maleate). We are sending a partial response.


These documents include information that is commercial confidential or otherwise protected from disclosure to the public under the Freedom of Information Act (Title 5, *United States Code* [U.S.C.] 552) and FDA regulations. The Committee should not publish or otherwise make public any such information. We would be glad to discuss with the Committee staff the protected status of any specific information.

We have reprinted the questions to which we are now responding in bold. We are sending two boxes of documents that are responsive to the following two questions:

- 2. All documents, e-mails, and memoranda from or to Dr. Johann-Liang related to rosiglitazone (Avandia) and pioglitazone (Actos).**
- 3. All documents, e-mails, and memoranda from or to Dr. Mark Avigan related to rosiglitazone (Avandia) and pioglitazone (Actos).**

Thank you again for your interest in this matter. If you have any further questions, please let us know. A similar letter with the enclosures has been sent to Chairman Dingell.

Sincerely,

 Stephen R. Mason
Acting Assistant Commissioner
for Legislation